Stay up to date with the latest news, trials, and upcoming events from A.N.T.

Advanced NanoTherapies (ANT) Secures $4M Strategic Investment to Accelerate Clinical Development of SirPlux Duo Drug-Coated Balloon (DCB)for Treating de novo Coronary Artery Disease (CAD)

Advanced NanoTherapies Inc. (ANT), a clinical-stage medical device company committed to solving the most significant challenges in vascular disease through the creative applications of nanotechnology, today announced a $4M Series A extension from a prominent undisclosed strategic medical device company.

read more

SirPlux Duo Receives Breakthrough Designation

SirPlux Duo Receives Breakthrough DesignationOn May 28, 2021, the US Food and Drug Administration (FDA) granted Advanced NanoTherapies Breakthrough Designation for its SirPlux Duo device. SirPlux Duo is a drug-coated balloon (DCB) that leverages nanotechnology to...

read more

Advanced NanoTherapies Raises $5.3 Million in Seed-Round

Advanced NanoTherapies Raises $5.3 Million in Seed-RoundCompany accelerates development of its nanoparticle-based drug delivery technology platform to treat peripheral artery disease and other applicationsLOS GATOS, Calif. – October 13, 2020 – Advanced NanoTherapies,...

read more